(EMAILWIRE.COM, January 19, 2019 ) The lung cancer surgery market is projected to reach USD 29.99 billion by 2021 from USD 21.58 billion in 2016, at a CAGR of 6.8% from 2016 to 2021. The high incidence and prevalence of lung cancer and rise in healthcare expenditure, increasing lung cancer awareness campaigns, and technological advancements in the lung cancer treatment are the major factors fuelling the growth of this market.

This market is segmented based on device, procedure, and region. On the basis of device, the market is segmented into surgical instruments, monitoring and visualizing systems, and endosurgical equipment. In 2016, the surgical instrument segment is expected to account for the largest share of the market due to increasing prevalence of lung cancer and growing aging population.

Sample Report - https://www.marketsandmarkets.com/requestsampleNew.asp?id=222

On the basis of procedure, the market is classified into thoracotomy and minimally invasive surgeries. The thoracotomy segment further sub segmented into lobectomy, sleeve resection, segmentectomy, and pneumonectomy. In 2016, the thoracotomy segment is expected to account for the largest share of the market. This large share can be attributed to increasing technological advancements in lung cancer treatment.

Market Players:
Key players in the lung cancer surgery market include Ethicon US LLC (U.S.), Intuitive Surgical Inc. (U.S.), Olympus Corporation (Japan), Accuray Inc. (U.S.), AngioDynamics Inc. (U.S.), Teleflex Inc. (U.S.), KARL STORZ GmbH (Germany), Ackermann Instrumente GmbH (Germany), Scanlan International Inc. (U.S.), and Trokamed GmbH (Germany).